Exco InTouch, the leading provider of patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, today announced that it has now formally received U.S.- EU Safe Harbor Framework and U.S.- Swiss Safe Harbor Framework Self Certification status by the U.S. Department of Commerce’s International Trade Administration (ITA). The designation certifies that Exco InTouch’s practices meet or exceed the data privacy and security standards outlined by The European Commission’s Directive on data protection.
The U.S. Department of Commerce, in consultation with the European Commission, developed the Safe Harbor framework in order to bridge the gap between EU/Switzerland and U.S. approaches to privacy protection and provide a streamlined means for U.S. organisations to comply with the Commission’s Directive. In order to be recognised for the certification, Exco InTouch has demonstrated that its customer privacy procedures comply with the seven ‘Safe Harbor Privacy Principles’ which cover notice, choice, transfers to third parties, access, security, data integrity and enforcement. As a result, Exco InTouch’s customers, for whom the company provides mobile and digital patient engagement solutions, can be reassured that their programs comply with these stringent privacy and security safeguards.
“Protecting the privacy and confidentiality of personal information has always been, and will remain, the highest priority for Exco InTouch,” says Mike Hansen, COO and Co-Founder of Exco InTouch. “The U.S. – EU and US – Swiss Safe Harbor Certification will not only help to streamline our data transfer processes between the EU/Switzerland and U.S, but will also provide our customers with further reassurance that we are fully compliant with the highest standards of data protection.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.